Exact Sciences Corporation
EXAS
Rang in Aktien
#1153
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Aktienkurs
$104.91
Zuletzt synchronisiert: 2026-03-23
Marktkapitalisierung
$20.03B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
67.24%
Land
US
Handel Exact Sciences Corporation (EXAS)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Exact Sciences Corporation (EXAS)
Anzahl der ausstehenden Aktien zum December 2025: 189.74M
Laut den neuesten Finanzberichten und dem Aktienkurs von Exact Sciences Corporation beträgt die aktuelle Anzahl der ausstehenden Aktien 189.74M. Am Ende von December 2024 hatte das Unternehmen 184.20M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Exact Sciences Corporation (EXAS) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 189.74M | 0.56% |
| 2025 | 188.69M | 2.44% |
| 2024 | 184.20M | 2.25% |
| 2023 | 180.14M | 2.15% |
| 2022 | 176.35M | 2.92% |
| 2021 | 171.35M | 13.37% |
| 2020 | 151.14M | 15.15% |
| 2019 | 131.26M | 7.41% |
| 2018 | 122.21M | 5.64% |
| 2017 | 115.68M | 13.04% |
| 2016 | 102.34M | 11.07% |
| 2015 | 92.14M | 14.84% |
| 2014 | 80.23M | 18.87% |
| 2013 | 67.49M | 13.47% |
| 2012 | 59.48M | 13.27% |
| 2011 | 52.51M | 29.80% |
| 2010 | 40.46M | 23.37% |
| 2009 | 32.79M | 20.50% |
| 2008 | 27.21M | 0.99% |
| 2007 | 26.95M | 1.64% |
| 2006 | 26.51M | 0.91% |
| 2005 | 26.27M | 3.69% |
| 2004 | 25.33M | 33.96% |
| 2003 | 18.91M | 2.59% |
| 2002 | 18.43M | 11.80% |
| 2001 | 16.49M | 1,027.91% |
| 2000 | 1.46M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 371.00M | 95.53% |
US
|
|
| 705.30M | 271.72% |
US
|
|
| 143.28M | -24.49% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 48.63% |
US
|
